Simin J, et al. - Researchers undertook this prospective Swedish population based matched-cohort analysis to assess the risk of ovarian cancer in relation to different menopausal hormone therapy (MHT) options. Participants were women ≥ 40 years who have received systemic MHT between 2005-2012 (288,950 ever-users). These were group-level matched (1:3) to 866,546 non-users. They used the Swedish Prescribed Drug Registry to establish MHT use and connected the data to various national health data registries. A modestly increased risk of ovarian cancer was reported in relation to current EP-MHT use, while no consistent risk was identified among past users. An increased risk was observed in relation to current continuous testosterone derived regimens. A marginally increased risk was noted in relation to progesterone derived regimens. Overall, a modestly increased risk of ovarian cancer was observed in relation to EP-MHT, notably continuous regimens.